The journal Frontiers Computational Psychiatry has  published a methods article based on the performance of a clinical in silico test (ISCT) for a head-to-head comparison between Lisdexamfetamine and Methylphenidate, two compounds used to treat patients with ADHD. It is a collaborative project between the Catalan company Anaxomics  Biotech, Takeda, the Hospital  Perpetuo Socorro in Badajoz, the Hospital Infanta  Leonor in Madrid, the Institute of Biotechnology and Biomedicine (IBB, of the UAB), the GRIB (from UPF) and the ICREA institution.

Anaxomics' TPMS (Therapeutic  Performance Mapping System) technology has made it possible to simulate and model via Quantitative Pharmacology of Systems (QSP) 2,600 adult and paediatric patients with and without the main psychiatric comorbidities: depression, anxiety, bipolar disorder, twitches.

The application of this type of technology for the modelling and analysis of ISCT helps with the generation of new hypotheses, allowing to meet a great molecular detail on the most optimal treatment based on the patient's profile, while saving resources and time in the development and improvement of therapies.

METHODS article

Front. Psychiatry, 03 November 2021 | https://doi.org/10.3389/fpsyt.2021.741170

You may also be interested in:

• Anaxomics, Novartis and Münster Children's Hospital analyse six treatments for Still's disease with artificial intelligence
• Oncotarget publishes study by ICO, Takeda, Anaxomics and UPF on brigatinib and alectinib to treat lung cancer
• Anaxomics inaugurates headquarters in Barcelona to continue growth in 2020